{"docid":"VWS-WOO-Spc2-1122269","collapsed":true,"count":1,"unchecked":0,"snapshots_total":3,"versions":[{"archive_id":"folder_import_388_959f35840c4395e1f6c486b73cbd2f3b","bestandsnaam":"VWS-WOO-Spc2-1122269.pdf","created_date":"2025-11-13 19:19:45","last_seen":"2025-11-13 19:19:45","from_file":"folder_import","bron":"/volume3/websites/openrijksoverheid/documenten_files/VWS-WOO-Spc2-1122269.pdf","snippet":"1122269\n\n50-55700-98-900\n\n“Open label 1:1:1 cluster randomized controlled trial of chloroquine, hydroxychloroguine or no\n\ntreatment in patents with admitted with moderate to severe COVID-19 (ARCHAIC)”","digest":"3e348633e7b4","dupes":3,"date_to":"2025-11-13 19:19:45","date_from":"2025-10-04 01:21:08","unchecked":false}],"raw":[{"archive_id":"folder_import_388_959f35840c4395e1f6c486b73cbd2f3b","bestandsnaam":"VWS-WOO-Spc2-1122269.pdf","created_date":"2025-11-13 19:19:45","last_seen":"2025-11-13 19:19:45","from_file":"folder_import","bron":"/volume3/websites/openrijksoverheid/documenten_files/VWS-WOO-Spc2-1122269.pdf","snippet":"1122269\n\n50-55700-98-900\n\n“Open label 1:1:1 cluster randomized controlled trial of chloroquine, hydroxychloroguine or no\n\ntreatment in patents with admitted with moderate to severe COVID-19 (ARCHAIC)”","digest":"3e348633e7b4"},{"archive_id":"folder_import_388_dce02904a4e00f4913d09b180a939d88","bestandsnaam":"VWS-WOO-Spc2-1122269.pdf","created_date":"2025-11-13 17:50:39","last_seen":"2025-11-13 17:50:39","from_file":"folder_import","bron":"documenten_files/VWS-WOO-Spc2-1122269.pdf","snippet":"1122269\n\n50-55700-98-900\n\n“Open label 1:1:1 cluster randomized controlled trial of chloroquine, hydroxychloroguine or no\n\ntreatment in patents with admitted with moderate to severe COVID-19 (ARCHAIC)”","digest":"3e348633e7b4"},{"archive_id":"VWS-WOO-4096451-1081744-d00-1f09d9e8-2505-6ab8-a3e2-a5573eed69c6.zip_169","bestandsnaam":"VWS-WOO-Spc2-1122269.pdf","created_date":"2025-10-04 01:21:08","last_seen":"2025-10-04 01:21:08","from_file":"VWS-WOO-4096451-1081744-d00-1f09d9e8-2505-6ab8-a3e2-a5573eed69c6.zip","bron":"/volume3/websites/openrijksoverheid/archieven_files/VWS-WOO-4096451-1081744-d00-1f09d9e8-2505-6ab8-a3e2-a5573eed69c6.zip","snippet":"1122269    50-55700-98-900    “Open label 1:1:1 cluster randomized controlled trial of chloroquine, hydroxychloroquine or no  treatment in patients with admitted with moderate to severe COVID-19 (ARCH","digest":"3e348633e7b4"}],"filename":"ONDER EMBARGO samenvatting projecten eerste wave COVID-19.docx","truncated":false,"elapsed_ms":11}